Article | September 26, 2022

RBQM For Decentralized Trials: Two Key Areas Of Focus To Reduce Your Risk

Source: Cmed Clinical Research Services

Whilst the implementation of RBQM is growing, the use of the term ‘risk’ in RBQM could still be hindering implementation or buy-in within organizations because a risk may be thought of as ‘bad’. However, a risk is merely a potential future issue, while an issue is a current problem that requires resolution. 

Today, many industry resources focus on how to approach RBQM and why sponsors should be moving to implementation, including interpreting what is required and how to get started. However, these articles tend to cover items 5.0.1 through to 5.0.4 as per ICH-GCP E6 R2, when in fact the true “heavy lifting” starts at Sections 5.0.5: ‘Risk Communication’ and 5.0.6: ‘Risk Review.’ This article takes a more in-depth look at these two sections to show how the implementation of RBQM can reduce issues and achieve holistic trial oversight in today’s complex decentralized trials.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader

Cmed Clinical Research Services